Cargando…

HER2 Expression Status and Prognostic, Diagnostic, and Demographic Properties of Patients with Gastric Cancer: a Single Center Cohort Study from Iran

BACKGROUND: The fourth most prevalent cancer worldwide and a major cause of death in developing countries is gastric cancer (GC). Human epidermal growth factor receptor 2 (HER2), is a proto-oncogene expressed in different solid tumors. This study aimed to evaluate possible associations of HER2 expre...

Descripción completa

Detalles Bibliográficos
Autores principales: Feizy, Abdolamir, Karami, Aida, Eghdamzamiri, Reza, Moghimi, Minoosh, Taheri, Hadi, Mousavinasab, Nouraddin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103572/
https://www.ncbi.nlm.nih.gov/pubmed/29938472
http://dx.doi.org/10.22034/APJCP.2018.19.6.1721
_version_ 1783349363345457152
author Feizy, Abdolamir
Karami, Aida
Eghdamzamiri, Reza
Moghimi, Minoosh
Taheri, Hadi
Mousavinasab, Nouraddin
author_facet Feizy, Abdolamir
Karami, Aida
Eghdamzamiri, Reza
Moghimi, Minoosh
Taheri, Hadi
Mousavinasab, Nouraddin
author_sort Feizy, Abdolamir
collection PubMed
description BACKGROUND: The fourth most prevalent cancer worldwide and a major cause of death in developing countries is gastric cancer (GC). Human epidermal growth factor receptor 2 (HER2), is a proto-oncogene expressed in different solid tumors. This study aimed to evaluate possible associations of HER2 expression status with survival rate, age, sex, tumor grade, histopathological type, and primary tumor location in patients with GC. METHODS: Subjects were enrolled in this cohort study after consideration of inclusion and exclusion criteria. Biopsy specimens were stained using immunohistochemistry. Samples with a score of 3+ were considered to exhibit HER2 overexpression. The mentioned variables were extracted from patients’ files as well as by clinical evaluation. The Kaplan-Meier method was applied for analyzing the survival rate and Chi square for possible factor associations. RESULTS: A total of 210 patients (25.2% female and 74.8% male) were enrolled. In a 5-year follow-up (adherence rate: 45.7%), the average survival was 9.4±10.9 months. HER2 overexpression was evident in 24%. There was no statistically significant association found between HER2 expression and primary tumor location (p-value=0.63), histopathological type (p-value=0.72), or tumor grade (p-value=0.051). Furthermore, no statistically significant links were apparent with tumor grade in either male or female groups as well as patients aged ≥60 and <60 years (all p-values >0.05). Moreover, no statistically significant association was detected between HER2 expression status (p-value=0.88), sex (p-value=0.31), and age (p-value=0.055) with patient survival. CONCLUSIONS: No statistically meaningful association was found between all parameters examined and HER2 expression status. Divergence of the results from earlier studies might be due to genetic variation. Thus, performing a meta-analysis on certain races might be helpful for clarification.
format Online
Article
Text
id pubmed-6103572
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-61035722018-08-28 HER2 Expression Status and Prognostic, Diagnostic, and Demographic Properties of Patients with Gastric Cancer: a Single Center Cohort Study from Iran Feizy, Abdolamir Karami, Aida Eghdamzamiri, Reza Moghimi, Minoosh Taheri, Hadi Mousavinasab, Nouraddin Asian Pac J Cancer Prev Research Article BACKGROUND: The fourth most prevalent cancer worldwide and a major cause of death in developing countries is gastric cancer (GC). Human epidermal growth factor receptor 2 (HER2), is a proto-oncogene expressed in different solid tumors. This study aimed to evaluate possible associations of HER2 expression status with survival rate, age, sex, tumor grade, histopathological type, and primary tumor location in patients with GC. METHODS: Subjects were enrolled in this cohort study after consideration of inclusion and exclusion criteria. Biopsy specimens were stained using immunohistochemistry. Samples with a score of 3+ were considered to exhibit HER2 overexpression. The mentioned variables were extracted from patients’ files as well as by clinical evaluation. The Kaplan-Meier method was applied for analyzing the survival rate and Chi square for possible factor associations. RESULTS: A total of 210 patients (25.2% female and 74.8% male) were enrolled. In a 5-year follow-up (adherence rate: 45.7%), the average survival was 9.4±10.9 months. HER2 overexpression was evident in 24%. There was no statistically significant association found between HER2 expression and primary tumor location (p-value=0.63), histopathological type (p-value=0.72), or tumor grade (p-value=0.051). Furthermore, no statistically significant links were apparent with tumor grade in either male or female groups as well as patients aged ≥60 and <60 years (all p-values >0.05). Moreover, no statistically significant association was detected between HER2 expression status (p-value=0.88), sex (p-value=0.31), and age (p-value=0.055) with patient survival. CONCLUSIONS: No statistically meaningful association was found between all parameters examined and HER2 expression status. Divergence of the results from earlier studies might be due to genetic variation. Thus, performing a meta-analysis on certain races might be helpful for clarification. West Asia Organization for Cancer Prevention 2018 /pmc/articles/PMC6103572/ /pubmed/29938472 http://dx.doi.org/10.22034/APJCP.2018.19.6.1721 Text en Copyright: © Asian Pacific Journal of Cancer Prevention http://creativecommons.org/licenses/BY-SA/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
spellingShingle Research Article
Feizy, Abdolamir
Karami, Aida
Eghdamzamiri, Reza
Moghimi, Minoosh
Taheri, Hadi
Mousavinasab, Nouraddin
HER2 Expression Status and Prognostic, Diagnostic, and Demographic Properties of Patients with Gastric Cancer: a Single Center Cohort Study from Iran
title HER2 Expression Status and Prognostic, Diagnostic, and Demographic Properties of Patients with Gastric Cancer: a Single Center Cohort Study from Iran
title_full HER2 Expression Status and Prognostic, Diagnostic, and Demographic Properties of Patients with Gastric Cancer: a Single Center Cohort Study from Iran
title_fullStr HER2 Expression Status and Prognostic, Diagnostic, and Demographic Properties of Patients with Gastric Cancer: a Single Center Cohort Study from Iran
title_full_unstemmed HER2 Expression Status and Prognostic, Diagnostic, and Demographic Properties of Patients with Gastric Cancer: a Single Center Cohort Study from Iran
title_short HER2 Expression Status and Prognostic, Diagnostic, and Demographic Properties of Patients with Gastric Cancer: a Single Center Cohort Study from Iran
title_sort her2 expression status and prognostic, diagnostic, and demographic properties of patients with gastric cancer: a single center cohort study from iran
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103572/
https://www.ncbi.nlm.nih.gov/pubmed/29938472
http://dx.doi.org/10.22034/APJCP.2018.19.6.1721
work_keys_str_mv AT feizyabdolamir her2expressionstatusandprognosticdiagnosticanddemographicpropertiesofpatientswithgastriccancerasinglecentercohortstudyfromiran
AT karamiaida her2expressionstatusandprognosticdiagnosticanddemographicpropertiesofpatientswithgastriccancerasinglecentercohortstudyfromiran
AT eghdamzamirireza her2expressionstatusandprognosticdiagnosticanddemographicpropertiesofpatientswithgastriccancerasinglecentercohortstudyfromiran
AT moghimiminoosh her2expressionstatusandprognosticdiagnosticanddemographicpropertiesofpatientswithgastriccancerasinglecentercohortstudyfromiran
AT taherihadi her2expressionstatusandprognosticdiagnosticanddemographicpropertiesofpatientswithgastriccancerasinglecentercohortstudyfromiran
AT mousavinasabnouraddin her2expressionstatusandprognosticdiagnosticanddemographicpropertiesofpatientswithgastriccancerasinglecentercohortstudyfromiran